We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App





New Test that Measures Antibodies in Girls Who Have Received HPV Vaccine Presented at AACC 2021

By LabMedica International staff writers
Posted on 29 Sep 2021
Print article
Illustration
Illustration

A new test to measure antibodies in girls who have received a vaccine for human papilloma virus (HPV), the leading cause of cervical cancer in women, was presented at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo.

Developed by scientists at the University of Energy and Natural Resources (Sunyani, Ghana), the new test could help resolve persistent challenges in healthcare for women.

HPV is one of the most common sexually transmitted viruses, and research has clearly linked HPV infections to reproductive cancers in both women and men. In particular, most cases of cervical cancer are caused by HPV infection, which means that vaccinating girls against HPV is key to preventing and eliminating this cancer. Determining how long protection from HPV lasts after vaccination could help to bolster public confidence in the vaccine and increase uptake. With this in mind, a team of scientists created a rapid, high-throughput test to detect and quantify antibodies against HPV in Ghanaian girls. The scientists validated their test with blood samples from 49 pre-adolescent girls who received a quadrivalent HPV vaccine and 40 age-matched, unvaccinated girls. The test showed that immunoglobulin G antibodies for HPV-16 and -18 (common types of HPV) were much more prevalent among vaccinated girls three years after the third dose of the vaccine compared with unvaccinated girls (63.3% vs. 12.5% for HPV-16).

“Our results provide empirical evidence that the initial antibody response is sustained even at 36 months post-vaccination and around the average age of sexual debut for African girls,” said Emmanuel Donkoh, PhD, of the University of Energy and Natural Resources who led the team. “The higher HPV-16 and -18 antibodies among vaccinated girls emphasize the need to scale-up HPV vaccination among girls in the country.”

Related Links:
University of Energy and Natural Resources 

Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Centromere B Assay
Centromere B Test
New
Bordetella Pertussis Molecular Assay
Alethia Pertussis

Print article
ADLM

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The AI-based method can more accurately detect antibiotic resistance in deadly bacteria such as tuberculosis and staph (Photo courtesy of Adobe Stock)

New AI-Based Method Improves Diagnosis of Drug-Resistant Infections

Drug-resistant infections, particularly those caused by deadly bacteria like tuberculosis and staphylococcus, are rapidly emerging as a global health emergency. These infections are more difficult to treat,... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.